Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Quallent Pharmaceuticals","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira\u00ae (adalimumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CAYMAN ISLANDS","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Quallent Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Expands Access to Adalimumab-Adbm Injection, the Company's Biosimilar to Humira\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CAYMAN ISLANDS","productType":"Large molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Quallent Pharmaceuticals

    Menu

    Quallent Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Quallent Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Cayman Islands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Boehringer Ingelheim Expands Access to Adalimumab-Adbm Injection, the Company's Biosimilar to Humira®

              Details:

              Under the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo (adalimumab-adbm) injection and Adalimumab-adbm.

              Lead Product(s): Adalimumab

              Therapeutic Area: Immunology Product Name: Cyltezo

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Boehringer Ingelheim GmbH

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 13, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Quallent Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Cayman Islands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

              Details:

              Alvotech will manufacture its high-concentration interchangeable biosimilar, AVT02, a monoclonal antibody and that has been approved as a biosimilar to Humira (adalimumab) for Quallent.

              Lead Product(s): Adalimumab

              Therapeutic Area: Immunology Product Name: AVT02

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Alvotech

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY